Our Work

On 8 and 9 November 2022, the Maternal Immunization Working Group (MIWG) held an in-person and online hybrid meeting. The objectives of the[...]

Within the context of the Covid19 Vaccine Introduction Program (COVIP), the CARESAFE project builds on existing CDC and Task Force for Global Health[...]

Rare adverse events following immunization (AEFIs) occurring in <1 per 10,000 vaccine recipients may not be detected in prelicensure clinical trials. The success[...]

Effective safety monitoring of COVID-19 vaccines must go beyond the use of passive surveillance, which is typically used to monitor vaccine safety and generate a hypothesis, to the use of active surveillance[...]

Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO; ex-V3SWG)    In recognition of the increasing importance of viral vectors for the development of new[...]

The Coalition for Epidemic Preparedness Innovations (CEPI) mission is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable[...]

Randomised controlled trials (RCTs) are considered the gold standard for assessing the efficacy of drugs prior to their approval for use in the[...]

Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To[...]

Immunization in pregnancy is a promising public health strategy to reduce illness and death among pregnant women and young infants. This is particularly[...]

The Brighton Collaboration (BC) Viral Vector Vaccines Safety Working Group (V3SWG) was renamed to Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) in July[...]